The migraine signature study: Methods and baseline results
- PMID: 33368248
- PMCID: PMC8048806
- DOI: 10.1111/head.14033
The migraine signature study: Methods and baseline results
Abstract
Objective: To characterize patients who utilize services for migraine in a large integrated health care network, and describe patterns of care and utilization.
Background: Within health care systems, migraine is a common reason for seeking primary and neurology care, but relatively little is documented about who seeks care and the factors that explain variation in utilization.
Methods: We conducted a retrospective cohort study using electronic health record (EHR) data from Sutter Health primary care (PC) patients who had at least one office visit to a PC clinic between 2013 and 2017. Migraine status was ascertained from diagnosis codes and medication orders. Control status was assigned to those with no evidence of care for any type of headache. We divided the primary care migraine cohort into two groups: those who received all their care for migraine from PC (denoted PC-M) and those who had ≥1 encounter with a neurologist for migraine (denoted N-M). Migraine cases were also designated as having preexisting migraine if they had an encounter with a migraine diagnosis within (±) 6 months of their first study period PC visit and, otherwise, designated as first migraine consult. Two levels of contrasts included: patients with migraine and controls; and within the group of patients with migraine, PC-M and N-M groups. Comorbid conditions were determined from EHR encounter diagnosis codes.
Results: We identified 94,149 patients with migraine (including 21,525 N-M and 72,624 PC-M) and 1,248,763 controls. Comorbidities: Proportions of psychiatric [29.8% (n = 28,054) vs. 11.8% (n = 147,043)], autoimmune [(4.4% (n = 4162) vs. 2.6% (n = 31,981)], pain [13.2% (n = 12,439) vs. 5.8% (n = 72,049)], respiratory [24.6% (n = 23,186) vs. 12.3% (n = 153,692)], neurologic [2.9% (n = 2688) vs. 0.9% (n = 11,321)], and cerebrovascular [1.0% (n = 945) vs. 0.6% (n = 7500)] conditions were higher in the migraine group compared to controls, all p < 0.001. Among patients with migraine, the N-M group was similar to the PC-M group in sex, age, ethnicity, and marital status, but were more likely to have preexisting migraine (49.9% (n = 10,734) vs. 36.2% (n = 26,317), p < 0.001). Proportions of comorbid conditions were higher among the N-M group than the PC-M group {psychiatric [38.5% (n = 8291) vs. 27.2% (n = 19,763)], autoimmune [6.3% (n = 1365) vs. 3.9% (n = 2797)], pain [19.6% (n = 4218) vs. 11.3% (n = 8211)], respiratory [30.3% (n = 6516) vs. 23.0% (n = 16,670)], neurologic [6.0% (n = 1288) vs. 1.9% (n = 1400)], cardiovascular [9.7% (n = 2091) vs. 7.0% (n = 5076)], and cerebrovascular [2.3% (n = 500) vs. 0.6% (n = 445)], all p < 0.001}. Medications: During the study period, 82.6% (n = 77,762) of patients with migraine received ≥1 prescription order for an acute migraine medication [89.4% (n = 19,250) of N-M vs. 80.6% (n = 58,512) of PC]. Opioids were prescribed to 52.9% (n = 49,837) of patients with migraine [63.5% (n = 13,669) for N-M and 49.8% (n = 36,168) for PC-M patients). During the study period, 61.4% (n = 57,810) of patients received ≥1 prescription for a migraine preventive medication [81.4% (n = 17,521) of N-M and 55.5% (n = 40,289) of PC-M patients]. The most commonly prescribed classes of preventive medications were antidepressants.
Conclusions: Among patients with migraine in a large health system, those who were also cared for in neurology were more likely to receive both acute and preventive medication migraine orders than those patients who did not see a neurologist, with triptans and antidepressants the most commonly prescribed classes of acute and preventive pharmacotherapies, respectively. Opioids were prescribed to approximately half of the total sample and more common in the N-M group. Adjusting for demographics, patients with migraine had higher rates of nearly every comorbidity we assessed and were more likely to utilize services compared to those without migraine. Overall, patients with migraine also cared for in neurology practices used more of all health care resource types under consideration and had more medical issues, which may be due in some part to a more severe, frequent and disabling disease state compared to those who sought care exclusively from PC practices.
Keywords: electronic health record; headache; health care system; migraine; neurology; primary care.
© 2020 Sutter Health Research. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC, on behalf of American Headache Society.
Conflict of interest statement
Dawn C. Buse has served as a consultant to Amgen/Novartis, Allergan, Biohaven, Eli Lilly, Promius/Dr. Reddy's, and Teva Pharmaceuticals. She is on the editorial board of
Figures
Similar articles
-
Impact of emergency department opioid use on future health resource utilization among patients with migraine.Headache. 2021 Feb;61(2):287-299. doi: 10.1111/head.14071. Epub 2021 Feb 18. Headache. 2021. PMID: 33599982
-
Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.Headache. 2018 Oct;58(9):1408-1426. doi: 10.1111/head.13407. Epub 2018 Oct 20. Headache. 2018. PMID: 30341895
-
Antidepressant medication use for primary care patients with and without medical comorbidities: a national electronic health record (EHR) network study.J Am Board Fam Med. 2010 Jul-Aug;23(4):499-508. doi: 10.3122/jabfm.2010.04.090299. J Am Board Fam Med. 2010. PMID: 20616292
-
Drug Interaction and Serotonin Toxicity with Opioid Use: Another Reason to Avoid Opioids in Headache and Migraine Treatment.Curr Pain Headache Rep. 2016 Aug;20(8):50. doi: 10.1007/s11916-016-0579-3. Curr Pain Headache Rep. 2016. PMID: 27457368 Review.
-
Epidemiology and treatment utilization for Canadian patients with migraine: a literature review.J Int Med Res. 2022 Sep;50(9):3000605221126380. doi: 10.1177/03000605221126380. J Int Med Res. 2022. PMID: 36173008 Free PMC article. Review.
Cited by
-
Understanding Data and Opportunities Focused on Value: A Single-Center Experience in Headache Care.Neurol Clin Pract. 2025 Feb;15(1):e200347. doi: 10.1212/CPJ.0000000000200347. Epub 2024 Oct 8. Neurol Clin Pract. 2025. PMID: 39399561 Free PMC article.
-
A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.Cephalalgia. 2022 Oct;42(11-12):1255-1264. doi: 10.1177/03331024221104180. Epub 2022 May 31. Cephalalgia. 2022. PMID: 35642092 Free PMC article.
-
Frequency, Demographics, Comorbidities, and Health Care Utilization by Veterans With Migraine: A VA Nationwide Cohort Study.Neurology. 2022 Oct 31;99(18):e1979-e1992. doi: 10.1212/WNL.0000000000200888. Neurology. 2022. PMID: 36100439 Free PMC article.
-
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open. 2022 Jun 1;5(6):e2215499. doi: 10.1001/jamanetworkopen.2022.15499. JAMA Netw Open. 2022. PMID: 35675076 Free PMC article. Clinical Trial.
References
-
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789‐1858. - PMC - PubMed
-
- Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343‐349. - PubMed
-
- Stone J, Carson A, Duncan R, et al. Who is referred to neurology clinics? The diagnoses made in 3781 new patients. Clin Neurol Neurosurg. 2010;112(9):747‐751. - PubMed